Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-001027
Filing Date
2025-02-14
Accepted
2025-02-14 16:07:50
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10613
2 JOINT FILING AGREEMENT p25-0475exhibit99_1.htm EX-99.1 JOINT FILING 3661
  Complete submission text file 0000902664-25-001027.txt   16042
Mailing Address 399 PARK AVENUE, 25TH FLOOR NEW YORK NY 10022
Business Address 399 PARK AVENUE, 25TH FLOOR NEW YORK NY 10022 212-418-2100
EMINENCE CAPITAL, LP (Filed by) CIK: 0001107310 (see all company filings)

EIN.: 134036527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 600 W. FULTON STREET, SUITE 800 CHICAGO IL 60661
Business Address 600 W. FULTON STREET, SUITE 800 CHICAGO IL 60661 (312) 929-0993
Cresco Labs Inc. (Subject) CIK: 0001832928 (see all company filings)

EIN.: 981505364 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92428 | Film No.: 25628525
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)